CAP ’09 Media Hot Topics

Sunday, October 11

AP107 Nipple and Breast Skin Challenges: A Multidisciplinary Approach
8:00 – 10:00 AM
Lesions of the nipple and skin of the breast often present diagnostic and management issues for pathologists and their clinical colleagues. Optimal diagnoses require a multidisciplinary approach integrating facets of surgical pathology, dermatopathology, and clinical dermatology. This course will encompass recurrent areas of difficulty, including the differential diagnosis of clear cells in the nipple epidermis, infiltrative and pseudo-infiltrative lesions of the nipple, intraductal proliferations, vascular lesions of breast skin, post-radiation changes, as well as inflammatory breast carcinoma and its mimickers. Commonly encountered and rarer entities will be covered. Pertinent differential diagnoses will be extensively illustrated, integrating aspects of surgical pathology, dermatopathology, and clinical dermatology. Where appropriate, ancillary studies (e.g., immunohistochemistry) will be discussed, highlighting their strengths and limitations.

Faculty: Timothy W. Jacobs, MD, FCAP
          Alison Z. Young, MD, PhD, FAAD, FASDP

Media are welcome to attend this program. Drs. Jacobs and Young are available for media interviews.

CP101 Toxicology, Introduction to Methodology, Laboratory Service Application, and Clinical Correlation
8:00 – 11:30 AM
Drug screenings for patients may involve those for intentional or unintentional overdoses as well as monitoring for compliance. Pathologists may be asked to recommend further testing or interpret testing of commonly encountered drugs of abuse. The faculty will discuss the clinical toxicology of commonly encountered poisonings and toxidromes, and review basic analytical techniques for toxicology testing with a focus on immunoassay as the most commonly used technique, along with discussing the limitations of the immunoassay-based drug screen. In addition, the session will provide the framework to create the appropriate level of toxicology laboratory service based on clinical needs and laboratory resources. Finally, representative cases of poisoning scenarios as examples of how to utilize appropriate diagnostic tests and interpretations to determine etiology of the signs and symptoms will also be provided.

Faculty: Tai C. Kwong, PhD
         Barbarajean Magnani, MD, PhD, FCAP
         Wayne R. Markus, MD, FCAP

Media are welcome to attend this program. Drs. Kwong, Magnani, and Markus are available for media interviews.
Sunday, October 11 (cont.)

ST100 Embracing the Future: An Introduction to Virtual Microscopy and Telemedicine
8:00 – 11:30 AM
Telepathology and virtual slides are here today and are already impacting pathology practices. This half-day course will provide the working knowledge you need to understand telepathology and virtual slide basics, decide where these technologies may be applied within your practice, and anticipate their potential for future applications. Participants will learn about the essential components and operation of telepathology and virtual slide systems within the context of pathology practices for primary diagnosis, consultation, education and business models.

Faculty: Keith J. Kaplan, MD, FCAP
         Ronald S. Weinstein, MD, FCAP

*Media are welcome to attend this program. Drs. Kaplan and Weinstein are both available for media interviews.*

AP106 A Dozen Diagnostic Dilemmas of the Cervix and Endometrium
2:00 – 4:00 PM
Biopsies and resections of the cervix and endometrium are among the more common specimens seen in most practices of pathology. While most pathologists can recognize most invasive carcinomas in these sites without great difficulty, the distinction of significant precursor lesions from their benign mimickers remain highly problematic and common. The therapy and prognosis of histologic subtypes of carcinomas in these sites are markedly different, but their histologic distinction may be subtle. Similarly, the diagnostic criteria for some benign processes remain poorly defined. This course will address a series of issues that are both commonly encountered and highly challenging, for which textbooks and journal articles often provide insufficient material to permit confident resolution. The approach will be to frame each issue as a question and then to address the solution in a highly pragmatic fashion.

Faculty: Richard J. Zaino, MD, FCAP

*Media are welcome to attend this program. Dr. Zaino is available for media interviews.*
Monday, October 12

ST103 The Critical Role of Biospecimens in Personalized Health Care
8:00 – 9:30 AM
High-quality biospecimens are absolutely essential for the molecular testing that underlies personalized health care. High-quality biospecimens require optimal consenting, clinical annotation, collection, transportation, processing, storage, and transfer. The pathologist is the pivotal physician in these processes. Faculty will describe the rationale for creating high-quality biospecimens, what constitutes a high-quality biospecimen, and how pathologists are applying these concepts (National Community Cancer Center Program – NCCCP) in the community hospital.

Faculty: Carolyn C. Compton, MD, PhD, FCAP
Steven I. Gutman, MD, FCAP

Media are welcome to attend this program. Drs. Compton and Gutman are both available for media interviews.

ST105 Personalized Medicine: FDA Rules and Pathologists’ Responsibilities
10:00 – 11:30 AM
Laboratory tests are central to the current desire to implement personalized health care decision-making. Pathologists as developers, promoters, and gatekeepers to new tests are in a unique position to influence the future direction of this important practice area. New tests can enter the medical marketplace through FDA premarket review or as laboratory-developed tests under CLIA. Regulatory and scientific requirements differ markedly for these two different routes to market, and pathologists often fail to appreciate the differences in the opportunities and responsibilities afforded by these differing routes. Pathologists also are often unaware of the information sources available to help them make informed practice choices. This session is intended to take some of the mystery out of government regulatory processes and give practitioners a framework for providing leadership in making informed personalized health care testing choices.

Faculty: Robert L. Becker, MD, PhD, FCAP
Elizabeth A. Mansfield, PhD

Media are welcome to attend this program. Drs. Becker and Mansfield are not available for media interviews.
AP113 Mimickers in Breast Pathology
2:00 – 4:00 PM
Breast lesions that mimic others morphologically often present diagnostic challenges for pathologists in their daily practice. For example, diagnostic errors may be false positive when benign lesions are mistaken for in situ or invasive carcinomas or conversely false-negative when malignant lesions are interpreted as benign entities. This course will include common as well as rare mimickers in breast pathology and will provide diagnostic strategies useful in recognizing and distinguishing these potentially hazardous cases. Topics to be covered include invasive and pseudoinvasive lesions, in situ carcinomas and their mimickers, papillary lesions, spindle cell and fibroepithelial lesions, and metastases to and from the breast. Morphologic features will be strongly emphasized throughout with integration of ancillary techniques, such as immunohistochemistry, highlighting their strengths and limitations. Following this session, participants will be able to log on to www.cap.org and complete a related self-assessment module.

Faculty: Timothy W. Jacobs, MD, FCAP

Media are welcome to attend this program. Dr. Jacobs is available for media interviews.

CP105 Blood Management: Nuts and Bolts – The Role of Pathologists in Getting It Going
2:00 – 4:00 PM
Great progress has been made in advancing blood safety over the last three decades; however, a number of adverse transfusion outcomes (e.g., emerging infectious agents, TRALI, and transfusion-transmitted sepsis) remain concerns. Steps to mitigate residual threats will limit the number of available donor units and increase cost. Also, emerging data links blood transfusion with a number of other poor patient outcomes such as higher mortality rates and increased length of hospital stays. An aging population, more aggressive medical therapies, and recent limitations on erythropoiesis-stimulating agent (ESA) therapy for treatment of oncology-related anemia are projected to increase blood demand. Thus, strategies to promote more appropriate blood use should prove important in the coming years. This course will review the rationale for blood management and address the significance of this activity for the hospital pathologist.

Faculty: Arthur W. Bracey, MD, FCAP
Timothy Hannon, MD, MBA

Media are welcome to attend this program. Drs. Bracey and Hannon are available for media interviews.
Tuesday, October 13

VM104 Breast Predictive Factors: HER2 IHC Test Interpretation Accuracy – Video Microscopy Tutorial
8:00 – 9:30 AM
The evaluation and interpretation of HER2 immunohistochemistry (IHC) results is critical to selecting the most appropriate treatment regimen for women with breast cancer. This Video Microscopy Tutorial, taught by expert faculty, addresses proper HER2 IHC test interpretation, evaluation, and reporting through the presentation of virtual images from real patient cases. This interactive session will address specimen requirements, testing methodologies, performance challenges in ensuring testing accuracy, and factors influencing the quality of final test results, such as tissue fixation variables and staining artifacts, proper use and interpretation of controls, and assay exclusion criteria. The course targets an audience of pathologists who perform and/or interpret HER2 testing. Following this session, participants will be able to log on to www.cap.org and complete a related self-assessment module.

Faculty: David G. Hicks, MD, FCAP
Media are welcome to attend this program. Dr. Hicks is available for media interviews.

AP118 Radiologic and Pathologic Correlation of Mammographic Calcifications/Nodules of Breast Biopsy and Fine-Needle Aspiration
8:00 – 11:30 AM
Optimal management of patients with breast lesions requires a multidisciplinary approach. As an increasing number of imaging-guided biopsies are done for screen-detected abnormalities, the cooperation between radiologists and pathologists is establishing concordance between radiologists and pathologic findings is critical in the appropriate management of patients. The Breast Imaging Reporting and Data System (BI-RADS) is used by radiologists to classify mammographic/imaging abnormalities and help standardize the radiology report. Pathologists need a basic understanding of the imaging features of breast lesions and the variation encountered with the use of BI-RADS. Faculty will address some of the challenges faced in establishing agreement and appropriate patient management when the findings are incongruent, including the pitfalls and challenges of fine-needle aspiration. Following this session, participants will be able to log on to www.cap.org and complete a related self-assessment module

Faculty: Gilda Cardenosa, MD, MS
William J. Frable, MD, FCAP
Michael O. Idowu, MD, MPH, FCAP
Media are welcome to attend this program. Drs. Cardenosa and Frable are available for media interviews. However, Dr. Idowu is not available.
CP108 Point of Care Testing: A Tale of Three Institutions
8:00 – 11:30 AM
The number of point of care (POC) analytes and the frequency of their measurement has been increasing over the past 20 years and is expected to grow in the future. As the needs of medical centers vary, each institution’s medical staff has developed its own approach to POC, which presents challenges in solving unique problems associated with these customized programs. Expert faculty, each representing medical centers with widely divergent POC programs, will describe the scope of POC testing within their settings and present two POC examples they employ, indicating the principles of the test, reasons for implementation, advantages of POC testing, and problems associated with testing. Technologies discussed will include well-established analytes such as glucose, electrolytes, blood gases, coagulation tests, and emerging procedures for HIV and Helicobacter pylori detection. Practical approaches to technology selection, implementation, result integration, competency assessment, and physician credentialing will be discussed.

Faculty: Peter J. Howanitz, MD, FCAP

Media are welcome to attend this program. Dr. Hart is available for media interviews.

ST106 Genetic Testing: Principles Applied to Case Studies
8:00 – 11:30 AM
With completion of the Human Genome Project and the increasing diversity and demand for genetic tests, pathologists can expect more requests for pre-test consultation and support for the interpretation of genetic testing results. Following an introduction to genetic principles and terminology, this half-day course will employ case studies to focus on everyday issues encountered in clinical consultation requests for genetic testing. Important principles in the interpretation of results for “simple” (eg, hypercoagulation) or more involved (eg, pharmacogenetic, cystic fibrosis, hereditary cancer, DNA sequence-based) genetic tests will be discussed. Examples illustrating approaches to controlling send-out testing and its costs will also be presented. Audience discussion time follows each speaker.

Faculty: Daniel J. Bellissimo, PhD, FACMG
Jeffrey A. Kant, MD, PhD, FCAP
Karen E. Weck, MD, FCAP

Media are welcome to attend this program. Drs. Kant and Weck are available for media interviews. However, Dr. Bellissimo is not available.
Wednesday, October 14

AP129 Selected Topics in Breast Pathology: Benign Breast Changes, Margin Evaluation, and an Approach to Sentinel Lymph Nodes
2:00 – 4:00 PM
This course will look at studies evaluating benign breast changes and the subsequent risk of developing breast cancer utilizing the Nurses Health Study data in comparison to other modern studies. A number of examples of usual ductal hyperplasia, and low-grade ductal carcinoma in situ will be shown. In addition, examples will be presented of minimal atypical lobular hyperplasia and lobular carcinoma in situ. The risk associated with these lesions will be defined. Additional topics to be discussed include the evolving and controversial area of columnar cell change through flat epithelial atypia, specimen and margin evaluation for patients considered for breast conservation, and the processing, evaluation, and significance of sentinel lymph nodes in breast cancer patients. Following this session, participants will be able to log on to www.cap.org and complete a related self-assessment module.

Faculty: James L. Connolly, MD, FCAP

Media are welcome to attend this program. Dr. Connolly is available for media interviews.

AP129 Testing for Human Papillomavirus in the Vaccine Era
2:00 – 3:30 PM
Human papillomavirus (HPV) is the principal cause of cervical carcinogenesis. Recently, vaccines have been developed that should have a profound effect on the incidence of cervical cancer and its precursor lesions in the population. In addition, tests for HPV have become widely utilized as a technique to aid in screening and triage for neoplastic disease. This course will illustrate the important principles of HPV biology, epidemiology, and the natural history of HPV-associated lesions. A discussion of HPV vaccine development, technology, and implementation strategies will lead to an understanding of how HPV vaccines may be utilized and what impact may be anticipated from their widespread implementation. Laboratory detection of HPV, as an important tool for cervical cancer screening, will be discussed with a presentation of the technologies available, their strengths and weaknesses, and how to properly implement such procedures in the laboratory. Validation methods and proper quality control/assurance measures will also be presented. Participants will receive a detailed overview of these important advances in cervical cancer control technology and procedures, which they may incorporate into their daily practice.

Faculty: Teresa M. Darragh, MD, FCAP
David C. Wilbur, MD, FCAP

Media are welcome to attend this program. Dr. Wilbur is available for media interviews. However, Dr. Darragh is not available.